Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:58 PM
Ignite Modification Date:
2025-12-24 @ 10:58 PM
NCT ID:
NCT02952469
Eligibility Criteria:
There will be no control group. For the study group the following inclusion and exclusion criteria will be followed.
INCLUSION CRITERIA
* Male
* Aged ≥ 18 years
* Histological diagnosis of adenocarcinoma of the prostate OR have a clinical diagnosis of prostate cancer and on active therapy or have received treatment for prostate cancer.
* Multifocal metastatic disease in either castrate sensitive or castrate resistant patients.
* May or may not be on hormonal therapy, chemotherapy, or radium therapy.
* If on hormonal therapy or chemotherapy, must be on it for at least 3 months.
* No plans to undergo prostate cancer therapy administration (with hormone therapy, chemotherapy, radium therapy, external radiation) between the two study exams.
* At least 2 metastatic soft tissue or bone lesions identified on conventional imaging (CT, MRI or bone scan).
* Karnofsky performance status of ≥ 50 (or ECOG/WHO equivalent)
* Ability to understand and willingness to sign a consent document.
EXCLUSION CRITERIA
* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring hospitalization, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Physical limitation that would limit compliance with the study requirements
* Current enrollment in a therapeutic clinical trial
Healthy Volunteers:
False
Sex:
MALE
Minimum Age:
18 Years
Study:
NCT02952469
Study Brief:
Protocol Section:
NCT02952469